Key Takeaways
- Jim Cramer cautioned against purchasing stocks with “parabolic” gains in tech and AI sectors, noting these rallies typically reverse quickly
- He believes superior value lies in undervalued, neglected stocks currently out of favor
- Cramer’s Charitable Trust purchased Johnson & Johnson during the stock’s recent decline
- He named J&J his top pharmaceutical pick over Eli Lilly, highlighting its drug pipeline and corporate restructuring
- Cramer emphasized the importance of balancing momentum names with undervalued positions in portfolios
During Monday’s episode of CNBC’s Mad Money, Jim Cramer urged viewers to abandon the pursuit of market-leading momentum stocks and instead focus on beaten-down names the crowd is overlooking.
According to Cramer, stocks experiencing “parabolic” rallies—particularly in the technology and artificial intelligence sectors—present significant risk for new buyers. He admitted that his own attempts to ride such explosive moves typically end in losses.
“Those are all too hot, hot, hot for me,” Cramer remarked, referencing surging semiconductor and AI-related equities.
Rather than jumping into names like Intel or Advanced Micro Devices, Cramer revealed he’s taking a contrarian approach. He’s accumulating shares of high-quality companies that have fallen from grace and been abandoned by Wall Street.
His CNBC Investing Club Charitable Trust recently added shares of Johnson & Johnson during the stock’s ongoing selloff. The healthcare sector currently ranks as the S&P 500’s worst performer year-to-date.
“We are buying it in freefall,” Cramer explained. “You don’t get to buy the best at a discount very often. When you do, you buy some.”
Cramer’s Bullish Case for Johnson & Johnson
Cramer revealed that Johnson & Johnson has replaced Eli Lilly as his preferred pharmaceutical investment. He pointed to the company’s robust drug development pipeline and strategic business overhaul as key drivers of his conviction.
Johnson & Johnson has systematically divested underperforming business units while intensifying its focus on pharmaceutical innovation. The healthcare giant boasts numerous compounds in advanced clinical trials alongside several recent regulatory approvals.
According to Cramer, the stock’s recent weakness stems primarily from market noise, especially litigation concerns surrounding talc-related lawsuits. He contends these worries have obscured the company’s genuine operational improvements.
Cramer also noted a recurring pattern with Johnson & Johnson’s quarterly reports. The stock frequently sells off following morning earnings releases, then rebounds once management’s conference call begins. “If it gets blasted, try to get some,” he advised.
Why Portfolio Balance Matters Now
Cramer’s fundamental message centered on intelligent portfolio construction. He warned that concentrating exclusively in high-momentum stocks creates vulnerability when market sentiment inevitably shifts.
“Your portfolio always needs to have a decent mix between what’s hot and what’s not,” he stated.
When a particular market sector loses favor, maintaining exposure to undervalued securities ensures you’ve got positions working in your favor. Cramer attributed this philosophy to lessons learned during his tenure at Goldman Sachs.
“They don’t all go up at once. To which I always said, but something should go up.”
Healthcare equities have endured substantial selling pressure throughout 2025. Johnson & Johnson shares have declined over the trailing twelve months, with the stock dropping approximately 1.57% in recent trading amid persistent sector-wide headwinds.
